Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable ...

Boehringer Ingelheim, a global leader in animal health, today announced that the U.S. Food and Drug Administration (FDA) has approved VETMEDIN (pimobendan) Chewable Tablets and VETMEDIN Solution ...

GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...

Boehringer Ingelheim advances IL-11 ... • BI 765423 has been developed to target IL-11, a key driver of fibrosis • The potential first-in-class inhibitor is an acquired asset from Enleofen with ...

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...

Speeding up drug discovery in the age of AI may come down to a concept that's comfortingly old-fashioned: Consulting a ...

-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic ...

A strategic partnership with CommonSpirit Health aims to increase adherence to evidence-based guidelines (EBGs), improving screening and diagnosis of cardio-kidney-metabolic (CKM) diseases -- The ...

Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a ...

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients ...

Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...